Immunogenicity and tolerability after two doses of non-adjuvanted, whole-virion pandemic influenza a (h1n1) vaccine in hiv-infected individuals

HIGHLIGHTS

  • who: Heimo Lagler and colleagues from the Department of Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Vienna, Austria, Department of Dermatology, Division of have published the research work: Immunogenicity and Tolerability after Two Doses of Non-Adjuvanted, Whole-Virion Pandemic Influenza A (H1N1) Vaccine in HIV-Infected Individuals, in the Journal: (JOURNAL) of May/21,/2012
  • what: The aim of this observational non-interventional prospective single-center study was to evaluate the immunogenicity and tolerability of two intramuscular doses of this novel vaccine in HIV-positive individuals. The committee . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?